Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes

Area of Science:

• Endocrinology
• Oncology
• Pathology

Background:

• CDC73 alterations are linked to specific parathyroid lesions.
• These include hyperparathyroidism-jaw tumor (HPT-JT) syndrome-associated adenomas, atypical parathyroid tumors (APTs), and parathyroid carcinomas (PCs).
• Loss of nuclear parafibromin expression is a marker for CDC73 alterations, defining parafibromin-deficient parathyroid tumors.

Purpose of the Study:

• To characterize parafibromin-deficient parathyroid tumors.
• To highlight the clinical significance of parafibromin loss in parathyroid tumor diagnosis and management.
• To underscore the association between parafibromin deficiency and HPT-JT syndrome.

Main Methods:

• Histopathological analysis of parathyroid tumors.
• Evaluation of parafibromin expression as a surrogate marker for CDC73 alterations.
• Correlation of tumor morphology and clinical behavior.

Main Results:

• Parafibromin-deficient tumors exhibit distinct morphologic features, including eosinophilic cytoplasm, perinuclear clearing, and hemangiopericytoma-like vasculature.
• These tumors may have a higher recurrence/metastasis rate compared to parafibromin-intact carcinomas.
• Loss of parafibromin expression helps identify clinically aggressive atypical parathyroid tumors and can indicate HPT-JT syndrome.

Conclusions:

• Parafibromin deficiency is a key feature of specific parathyroid tumors with distinct histology and behavior.
• Assessment of parafibromin expression is crucial for accurate diagnosis, risk stratification, and identification of HPT-JT syndrome.
• Recognizing these tumors impacts patient management, surveillance, and family screening.